Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone that has completed Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
IPO Year: 2014
Exchange: NASDAQ
Website: otonomy.com
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the appointment of Jill Broadfoot to its board of directors. "Jill is an excellent addition to the board with strong strategic, operational and financial expertise within the biopharmaceutical sector," said David A. Weber, Ph.D., president and CEO of Otonomy. "We are excited to welcome her as we continue our growth trajectory and make progress to achieving our clinical milestones." Since 2018, Ms. Broadfoot has served as chief financial officer (CFO) of aTyr Pharma, Inc., a biotherapeutics company. P
15-12G - OTONOMY, INC. (0001493566) (Filer)
EFFECT - OTONOMY, INC. (0001493566) (Filer)
EFFECT - OTONOMY, INC. (0001493566) (Filer)
EFFECT - OTONOMY, INC. (0001493566) (Filer)
POS AM - OTONOMY, INC. (0001493566) (Filer)
POS AM - OTONOMY, INC. (0001493566) (Filer)
POS AM - OTONOMY, INC. (0001493566) (Filer)
S-8 POS - OTONOMY, INC. (0001493566) (Filer)
S-8 POS - OTONOMY, INC. (0001493566) (Filer)
S-8 POS - OTONOMY, INC. (0001493566) (Filer)
SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company's shares would be suspended from trading on Nasdaq effective at the open of business on December 23, 2022. Following such suspension, the company's shares will be traded on the OTC Pink Market. As previously reported, on November 14, 2022, Otonomy received a notice from Nasdaq indicating that the Listing Qualifications Staff (the Staff) had determined to delist the company's securities unless the company timely requested a hearing before the Nasdaq Hearings Panel (the Pan
SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC) today announced that the company's board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution ("Plan of Dissolution") that would include the distribution of remaining cash to stockholders following an orderly wind down of the company's operations, including the proceeds from the sale of any pipeline assets. To reduce cost, Otonomy has implemented a reduction in workforce. These updates are discussed below. Evaluation of Strategic Options As previously reported, Otonomy initiated an evaluation of strategic options to realize value from its pipeline. The
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended September 30, 2022 and provided an update on its product pipeline and corporate activities. Otonomy Program and Corporate Activity Updates In August 2022, Otonomy announced that OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints in a Phase 2 clinical trial in tinnitus patients. Based on these results, Otonomy discontinued development of OTO-313 and implemented other measures to extend its cash runway. Th
Higher dose cohorts for OTO-413 demonstrated no clinically meaningful improvement for patients from baselineLack of activity compared to 0.3 mg dose evaluated in prior studies may be due to a complex dose-response relationship that has been observed with neurotrophinsOtonomy intends to explore strategic options to advance and realize value from its pipeline including both OTO-413 and OTO-825 SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the clinical evaluation of higher doses for OTO-413 (0.75 mg and 1.50 mg) in patients with hearing loss de
OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints across all timepointsCompany to discontinue development of OTO-313 and implement other measures to extend its cash runway Clinical focus shifts to OTO-413 following positive Phase 2a results in April 2022; top-line results for evaluation of higher dosing still expected in fourth quarter of 2022 SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the OTO-313 Phase 2 trial in tinnitus demonstrated no clinically meaningful benefit versus pla
Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line results expected in third quarter of 2022Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment completed for higher dose evaluation with top-line results expected in fourth quarter of 2022OTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023Current capital funds operations through multiple clinical readouts Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biop
SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2022 and provide a corporate update at 4:30 p.m. ET on July 25, 2022. A live webcast of the call will be available online in the investor relations section of Otonomy's website at www.otonomy.com and will be archived there for 30 days. To access the live call by phone, please go to this link (registration link), and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minu
SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the H.C. Wainwright Global Investment Conference (Hybrid Conference). A pre-recorded company presentation by the Otonomy management team will be available on the conference website beginning at 7 a.m. ET / 4 a.m. PT on May 24, 2022. A link to the presentation will also become available at the same time through the Events page of the company's website (www.otonomy.com). About OtonomyOtonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for n
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of preclinical data for OTO-825 at the upcoming American Society of Gene & Cell Therapy (ASGCT) Meeting being held May 16-19 in Washington, DC. Dr. Phillip Uribe from Otonomy will be making a podium presentation entitled "Preclinical Development of an AAV-based Gene Therapy (OTO-825) for Congenital Hearing Loss Due to GJB2 Deficiency" beginning at 11:15 a.m. ET on May 19. This presentation is included in the "Breakthroughs in Neuromuscular and Hearing Disorders" session of the ASGCT me
Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluationOTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results expected in August 2022; clinical safety evaluation of higher and bilateral dosing ongoingOTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023Current capital funds operations through multiple clinical readouts and into second half of 2023 Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today repor
3 - OTONOMY, INC. (0001493566) (Issuer)
4 - OTONOMY, INC. (0001493566) (Issuer)
4 - OTONOMY, INC. (0001493566) (Issuer)
4 - OTONOMY, INC. (0001493566) (Issuer)
4 - OTONOMY, INC. (0001493566) (Issuer)
4 - OTONOMY, INC. (0001493566) (Issuer)
4 - OTONOMY, INC. (0001493566) (Issuer)
4 - OTONOMY, INC. (0001493566) (Issuer)
4 - OTONOMY, INC. (0001493566) (Issuer)
4 - OTONOMY, INC. (0001493566) (Issuer)
HC Wainwright reiterated coverage of Otonomy with a rating of Buy and set a new price target of $5.50 from $10.00 previously
HC Wainwright & Co. reiterated coverage of Otonomy with a rating of Buy and set a new price target of $5.50 from $10.00 previously
Piper Sandler reiterated coverage of Otonomy with a rating of and set a new price target of $5.00 from $10.00 previously
Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line results expected in third quarter of 2022Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment completed for higher dose evaluation with top-line results expected in fourth quarter of 2022OTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023Current capital funds operations through multiple clinical readouts Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biop
SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2022 and provide a corporate update at 4:30 p.m. ET on July 25, 2022. A live webcast of the call will be available online in the investor relations section of Otonomy's website at www.otonomy.com and will be archived there for 30 days. To access the live call by phone, please go to this link (registration link), and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minu
Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluationOTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results expected in August 2022; clinical safety evaluation of higher and bilateral dosing ongoingOTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023Current capital funds operations through multiple clinical readouts and into second half of 2023 Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today repor
SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter 2022 and provide a corporate update at 4:30 p.m. ET on May 9, 2022. The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 5359095. A live webcast of the call will be available online in the investor relations section of Otonomy's website at www.otonomy.com and will be archived there for 30 days. About OtonomyOtonomy is a biopharmaceutical company de
Clinical benefit again observed for OTO-413 versus placebo for multiple efficacy endpoints based on responder analysis at both Days 57 and 85 Results support clinical activity and tolerability findings from previous Phase 1/2 trialEnrollment in higher dose cohorts is ongoing with results expected in second half of 2022Otonomy expects to initiate full dose-ranging Phase 2 efficacy trial by the end of 2022 Management will review results during a conference call today at 8:30 a.m. ET SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced positive to
SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2021 and provide a corporate update at 4:30 p.m. ET on February 28, 2022. The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 5169343. A live webcast of the call will be available online in the investor relations section of Otonomy's website at www.otonomy.com and will be archived there for 30 days. About OtonomyOtonomy is a biopha
OTO-313 Phase 2 trial in tinnitus ongoing with results expected in mid-2022Enrollment nearly complete in OTO-413 Phase 2a cohort in hearing loss with results moved forward to early in second quarter of 2022Initiating clinical safety evaluation of higher dosing for OTO-413 to support full dose-ranging Phase 2 efficacy trial expected to start by the end of 2022OTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023 Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial r
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the third quarter 2021 and provide a corporate update at 4:30 p.m. ET (1:30 p.m. PT) on November 10, 2021. The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 3812898. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.otonomy.com. About OtonomyOtonomy is a biopharmaceutical company
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2021 and provide a corporate update at 4:30 p.m. ET (1:30 p.m. PT) on August 4, 2021. The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 8157418. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.otonomy.com. About OtonomyOtonomy is a biopharmaceutical company dedic
FDA’s review confirms use of Negative Binomial model for analysis of primary endpoint in ongoing OTIVIDEX Phase 3 trial in Ménière’s disease; results still expected in first quarter of 2021Company finalizing design of Phase 2 trial for OTO-313 in tinnitus and expects to start study in the first quarter of 2021 SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided updates regarding the statistical analysis plan for the ongoing Phase 3 trial of OTIVIDEX in Ménière’s disease, and outlined plans for a Phase 2 trial of OTO-313 in tinnitus. OTIVIDEX: FDA’
SC 13G/A - OTONOMY, INC. (0001493566) (Subject)
SC 13G/A - OTONOMY, INC. (0001493566) (Subject)
SC 13G/A - OTONOMY, INC. (0001493566) (Subject)
SC 13G/A - OTONOMY, INC. (0001493566) (Subject)
SC 13D - OTONOMY, INC. (0001493566) (Subject)
SC 13G/A - OTONOMY, INC. (0001493566) (Subject)
SC 13G/A - OTONOMY, INC. (0001493566) (Subject)
SC 13G/A - OTONOMY, INC. (0001493566) (Subject)
SC 13G - OTONOMY, INC. (0001493566) (Subject)
SC 13G - OTONOMY, INC. (0001493566) (Subject)
Gainers Immuron (NASDAQ:IMRN) stock rose 42.9% to $2.3 during Monday's pre-market session. The market value of their outstanding shares is at $13.0 million. DBV Technologies (NASDAQ:DBVT) shares moved upwards by 27.11% to $1.5. The company's market cap stands at $281.9 million. Humanigen (NASDAQ:HGEN) shares rose 18.09% to $0.12. The company's market cap stands at $14.1 million. Owlet (NYSE:OWLT) stock moved upwards by 13.28% to $0.82. The market value of their outstanding shares is at $93.8 million. NeuBase Therapeutics (NASDAQ:NBSE) stock moved upwards by 13.06% to $0.24. The company's market cap stands at $7.9 million. The company's, Q4 earnings came out 3 days ago. Personalis (NASD
Gainers Immuron (NASDAQ:IMRN) shares increased by 37.9% to $2.22 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 17.1 million shares, making up 288523.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $12.6 million. Scopus BioPharma (NASDAQ:SCPS) shares increased by 25.0% to $0.1. As of 12:30 EST, this security is trading at a volume of 85.9K shares, making up 8.9% of its average full-day volume over the last 100 days. The company's market cap stands at $2.1 million. DBV Technologies (NASDAQ:DBVT) shares moved upwards by 21.18% to $1.43. As of 12:30 EST, DBV Technologies's stock is trading
OnFriday, 143 stocks hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Tesla (NASDAQ:TSLA). The smallest company in terms of market cap to set a new 52-week low was Quotient (NASDAQ:QTNT). BIT Mining (NYSE:BTCM)'s stock dropped the most, trading down 774.92% to reach a new 52-week low. Harbor Custom Dev (NASDAQ:HCDI)'s stock showed potential to rebound, rebounding up 0.0% after reaching a new 52-week low. The following stocks set new 52-week lows on Friday: Tesla (NASDAQ:TSLA) shares hit a yearly low of $121.02. The stock was down 3.15% on the session. Rivian Automotive (NASDAQ:RIVN) shares reac
Don’t forget to check out our premarket coverage here . Losers Powerbridge Technologies Co., Ltd. (NASDAQ:PBTS) fell 16% to $0.1054 in pre-market trading after jumping 29% on Wednesday. Powerbridge Technologies recently announced the strategic acquisition of DTI Group. Helius Medical Technologies, Inc. (NASDAQ:HSDT) shares fell 14.7% to $0.21 in pre-market trading. Maxim Group recently initiated coverage on the stock with a Buy rating and a $1 price target. Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) fell 8.8% to $0.4202 in pre-market trading after jumping over 40% on Wednesday. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) fell 8.4% to $1.74 in pre-market trading after the company repo
Gainers IceCure Medical Ltd (NASDAQ:ICCM) shares jumped 296% to $3.71 after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who cannot be offered kidney-preserving surgery. Avaya Holdings Corp. (NYSE:AVYA) gained 57% to $0.2384. Athenex, Inc. (NASDAQ:ATNX) surged 47% to $0.1991 after the company announced Quantum Leap Healthcare Collaborative reported a trial result of I-SPY2 trial for oral paclitaxel in combination with PD-1 and carboplatin in neoadjuvant breast cancer. Verona Pharma plc (NASDAQ:VRNA) shares climbed 40.5% to $18.71 after the company announced ensifentrine met primary and key secondary endpoints in t
Otonomy Inc's (NASDAQ:OTIC) board of directors has approved and adopted a Plan of Liquidation and Dissolution that would include the distribution of remaining cash to stockholders following an orderly wind-down of the company's operations, including the proceeds from the sale of any pipeline assets. As previously reported, Otonomy initiated an evaluation of strategic options. The company is currently discussing the potential sale of its pipeline assets. Related: At Higher Doses, Otonomy's OTO-413 Shows No Clinical Benefit In Hearing Loss. To reduce costs and in connection with the planned dissolution, Otonomy has reduced its workforce, including the termination of all employees, effec
Gainers IceCure Medical Ltd (NASDAQ:ICCM) shares rose 158% to $2.42 in pre-market trading after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who cannot be offered kidney-preserving surgery. Exicure, Inc. (NASDAQ:XCUR) shares rose 46% to $1.08 in pre-market trading. Exicure 10% owner CBI USA, Inc. acquired a total of 3,400,000 shares at an average price of $1.60. Verona Pharma plc (NASDAQ:VRNA) rose 39.3% to $18.80 in pre-market trading after the company reported positive results of its Phase 3 ENHANCE-1 trial evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease.